SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-24-028545
Filing Date
2024-02-08
Accepted
2024-02-08 17:41:56
Documents
1
Group Members
VERSANT SIDE FUND IV, L.P.VERSANT VANTAGE II GP, L.P.VERSANT VANTAGE II GP-GP, LLCVERSANT VANTAGE II, L.P.VERSANT VENTURE CAPITAL IV, L.P.VERSANT VENTURES IV, LLCVERSANT VENTURES VI GP, L.P.VERSANT VENTURES VI GP-GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d768185dsc13da.htm SC 13D/A 162397
  Complete submission text file 0001193125-24-028545.txt   164562
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Subject) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87213 | Film No.: 24610411
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A